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The term “abscopal” (ab-, a prefix meaning “position away 
from,” and scopus [Latin] meaning “mark or target for shooting 
at”) was first used by Mole in 1953 to describe the effects of ion-
izing radiation “at a distance from the irradiated volume but with-
in the same organism.”1 Radiotherapy (RT) induces immunogenic 
cell death, leading to the production and release of cytokines and 
chemokines in the tumor microenvironment, followed by infiltra-
tion of dendritic cells (DCs) into the tumor site. Activation of DCs, 
which act as antigen presenting cells, causes priming and expan-
sion of tumor-reactive T-cells within the irradiated tumor and in 
the draining lymph nodes. These activated, tumor-specific T-cells 
in-turn migrate and eliminate non-irradiated tumors, hence result-
ing in the abscopal effect.2
The mechanism of abscopal effect has long remained poorly 
understood. In 2004, Demaria et al.3 suggested that the abscopal 
effect may be immune-mediated. Preclinical models have estab-
lished that the abscopal effect is T-cell-dependent4 and results 
from radiation “priming” of the immune system.5 In recent years, 
the use of immune checkpoint inhibitors (ICIs), such as ipilimumab 
or pembrolizumab, has greatly increased the prevalence of absco-
pal effects among selected patients, including those with meta-
static melanoma.6,7
The mechanism underlying the increased abscopal effect fol-
lowing RT-ICI combination is unclear. In the current issue of Clini-
cal and Molecular Hepatology, Yoo et al.8 conducted a preclinical 
study to investigate this issue using a murine syngeneic hepato-
cellular carcinoma (HCC) model. After transplanting Hepa 1-6 
cells in both hind legs of immunocompetent C57BL/6 mice, they 
irradiated the tumors in primary sites and observed abscopal ef-
fects in the non-irradiated tumors, with or without anti-pro-
grammed cell death protein 1 (PD-1) antibodies. They reported 
significantly enhanced abscopal effect and increased infiltration 
of activated cytotoxic T-cells in both irradiated and non-irradiated 
tumors when combinatorial therapy with RT and anti-PD-1 anti-
bodies was employed. Previous studies on combinatorial therapy 
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with RT and immunotherapy dealt with orthotopic HCC models, 
thus allowing the observation of effect of the combinatorial treat-
ment on the primary tumor, though not necessarily the abscopal 
effect.9,10 In this context, Yoo et al.8 provides initial information on 
the impact of RT-immunotherapy combination on non-irradiated 
metastatic tumors using a murine HCC model. Many methods 
have been attempted to increase the prevalence of the abscopal 
effect, including the combination of RT with cytokines, stimula-
tion of DCs to activate tumor antigen-presentation, vaccination 
with autologous tumor cells, targeting Toll-like receptors, and 
combination of RT and ICIs.2 Cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) and anti-PD-1 are cell surface molecules which 
prevent T-cell activation or reinvigoration following chronic anti-
gen exposure. Inhibiting these T-cell checkpoints leads to greater 
anti-tumor T-cell activity.
Yoo et al.8 also showed that 16 Gy in two fractions inhibited the 
growth of both irradiated and non-irradiated tumors more effec-
tively with higher infiltration of cytotoxic T-cells compared to a 
single 8 Gy fraction. The authors concluded that these results in-
dicated “the potential radiation dose-dependency of the abscopal 
effect.” In recent years, the utilization of stereotactic body radio-
therapy (SBRT) has increased, and there are suggestions that hy-
po-fractionated RT, which delivers higher doses of radiation per 
treatment or fraction, is associated with increased incidence of 
abscopal effects. While conventional RT is mainly directed at in-
ducing apoptosis due to DNA damage, SBRT induces necrotic tu-
mor cell death, which is a prerequisite for inducing an antitumor 
immune response. Yoo et al.8 explained that there is a window for 
the doses per fraction likely to induce abscopal effect, and thus 
their choice of the hypofractionated regimen. Using a similar ex-
perimental design, Dewan et al.11 tried to find the optimal RT dose 
and fractionation to induce the abscopal effect in combination 
with immunotherapy. They injected TSA mouse breast cancer cells 
into both hind legs of syngeneic mice, and irradiated the primary 
site with three distinct RT regimens (20 Gy ×1, 8 Gy ×3, or 6 Gy 
×5 fractions). As a result, they reported that fractionated RT, not 
single-fraction RT, induced immune-mediated abscopal effect 
when combined with CTLA-4 blockade.11 Later, they showed that 
the balance between cytosolic DNA and DNA exonuclease Trex1 
activation plays a crucial role in the dose effect of RT-immuno-
therapy combination. RT induces accumulation of double-strand 
DNA in the cytosol, and cytosolic DNA activates the DNA sensor 
cyclic GMP-AMP synthase (cGAS) and its downstream effector, 
i.e., stimulator of interferon genes (STING). Activation of the 
cGAS/STING pathway results in interferon-β secretion by cancer 
cells, leading to DC recruitment and activation, which are essen-
tial for CD8+ T-cell priming and antitumor immunity. Dewan et 
al.11 showed that RT-induced cytosolic DNA accumulation is di-
rectly proportional to the fractional dose; however, doses above 
12–18 Gy per fraction caused activation of DNA exonuclease 
Trex1 and degradation of cytosolic DNA, leading to attenuation of 
the RT-induced immunologic response. In this context, 8 Gy used 
by Yoo et al.8 falls in the range of optimal fractional doses for in-
vestigating the mechanism underlying the abscopal effect.12 Many 
questions remain to be answered regarding the optimization of 
RT-ICI combination, including the sequence of RT and ICIs (wheth-
er ICI can be administered before RT, after RT, or concurrently). 
There have been suggestions that anti-PD-L1 therapy is more ef-
fective with concurrent administration, while anti-CTLA-4 therapy 
is more effective when provided prior to RT; trials involving ad-
ministration of multiple ICIs with RT are currently underway.13
Yoo et al.8 showed that a higher-dose radiation also increased 
activated DC counts in the tumor-draining lymph nodes (TDLNs), 
which had a higher expression of PD-L1. While irradiation of the 
tumor site is capable of T-cell priming and activation, TDLNs with 
high tumor antigen load can provide a rich tumor drainage net-
work and are important sites for DC-mediated antitumor T-cell 
stimulation, a critical step in T-cell activation with anti-PD-L1 
therapy.14 Deng et al.15 demonstrated that the STING signaling 
axis activated in DCs promotes an anti-tumor CD8+ T-cell re-
sponse with an increased frequency of interferon-γ+ CD8+ T-cells 
in TDLNs; and this phenomenon was also observed by Yoo et al.8 
While these two studies did not involve the irradiation of TDLNs, 
Buchwald et al.14 injected modified B16F10 cells in bilateral flanks 
of C57BL/6 mice and irradiated either one flank tumor (10 Gy ×1) 
and TDLNs (3 Gy ×3) or one flank tumor alone. They found that 
tumor irradiation stimulated the proliferation of total CD8+ T-cells 
and stem-like CD8+ T-cells, a subset of CD8+ T-cells that rapidly 
proliferate following CD8+ T-cell exhaustion by anti-PD-L1 thera-
py, in the TDLNs. In contrast, the irradiation of tumor and TDLNs 
resulted in a reduction in the abscopal effect as well as the num-
ber of total tumor-specific CD8+ T-cells and stem-like CD8+ T-cells 
in both the irradiated and unirradiated tumors.14 The role of 
TDLNs in mediating the abscopal effects—as investigated by Yoo 
et al.8 and others—is clinically significant and warrants further in-
vestigation, as the effect of RT-ICI combination on the abscopal 
effects may be compromised when patients are subjected to re-
gional nodal irradiation or surgical removal of LNs.
Albeit rare, a number of cases of abscopal effects occurring in 
HCC patients have been reported in the literature. These cases in-
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clude palliative RT for bone metastasis resulting in the regression 
of primary HCC,16,17 irradiation of inferior vena cava (IVC) invasion 
resulting in the regression of multiple intrahepatic metastases,18 
irradiation of a metastatic mediastinal lymph node resulting in the 
regression of lung metastasis,19 and irradiation of primary HCC or 
IVC resulting in the regression of multiple lung or pleural metasta-
ses.20,21 Chino et al.5 reported an unusual case of SBRT for primary 
lung cancer resulting in complete remission of primary HCC. Al-
though these clinical observations suggest the potential role of 
combining RT and ICIs for metastatic HCCs, the RT-ICI combina-
tion should not be investigated for the sole purpose of inducing 
an abscopal effect, until we have more sufficient data to support 
the benefit of such a practice. Recent preclinical and retrospective 
studies have shown promising results for the combinatorial thera-
py with RT and ICIs for advanced HCC.9,22 In this context, the 
study by Yoo et al.8 provides valuable insight into the mechanisms 
underlying enhanced abscopal effect of treating HCC with a com-
bination of RT and ICIs.
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